Neuphoria Ends Social Anxiety Program After AFFIRM-1 Trial Misses Primary Goals—Strategic Review and Merck Partnership in Focus
Phase 3 Results Lead to Strategic Shift
Neuphoria Therapeutics (NASDAQ:NEUP) has announced it will discontinue development of BNC210 for the acute treatment of social anxiety disorder (SAD) after the AFFIRM-1 Phase 3 trial failed to meet both its primary and secondary efficacy endpoints. The company’s focus now shifts toward a strategic review of its pipeline and business operations, with the goal of maximizing shareholder value and evaluating options for its future path.
Key Data: AFFIRM-1 Trial Outcomes at a Glance
The AFFIRM-1 Phase 3 study was designed to assess the effect of a single, acute dose of 225 mg BNC210 versus placebo in a simulated public speaking challenge—a known trigger for social anxiety symptoms. Results showed:
| Trial Parameter | Result |
|---|---|
| Primary Endpoint | Not Met |
| Secondary Endpoints | Not Met |
| Safety Profile | Favorable, consistent with prior studies |
While the drug’s safety and tolerability remained strong, efficacy outcomes did not show statistically significant improvements versus placebo across both primary and secondary measures.
PTSD Program and Cash Position Remain Solid
Despite the disappointment in SAD, Neuphoria plans to leverage previous positive findings with chronic BNC210 dosing to evaluate potential next steps in post-traumatic stress disorder (PTSD). A full portfolio and operational review is underway, with further company updates expected by year-end.
As of June 30, 2025, Neuphoria reported $14.2 million in cash and cash equivalents. This is projected to fund operations into the second fiscal quarter of 2027, giving the company a runway to realign strategy without immediate financial pressure.
Merck Partnership Provides Growth Opportunities
Amid the operational pivot, Neuphoria’s collaboration with Merck & Co. continues to hold promise. One lead asset, MK-1167—a positive allosteric modulator (PAM) for central nervous system indications—is being evaluated in a Merck-led Phase 2 trial in Alzheimer’s disease. Importantly, Merck covers all costs for this program, while Neuphoria is eligible to receive up to $450 million in milestone payments and royalties from potential net sales.
| Collaboration Details | Current Status |
|---|---|
| Asset in Merck Partnership | MK-1167 (PAM) in Phase 2 (Alzheimer's disease) |
| Potential Milestones | Up to $450 million |
| Royalty Eligibility | On net sales of licensed products |
This partnership provides Neuphoria with the potential for substantial non-dilutive capital, even as its lead clinical program in social anxiety concludes.
What’s Next for NEUP Investors?
The end of the SAD program is a setback, but Neuphoria’s financial health and partnerships provide strategic options. With the AFFIRM-1 outcome prompting a company-wide review and a pipeline that includes ongoing projects in PTSD and cognitive disorders, all eyes are now on how management allocates capital and restructures for long-term value.
Investors should watch for Neuphoria’s upcoming portfolio review and strategic decisions—particularly any news related to the Merck partnership milestones and next steps for BNC210 in other neuropsychiatric indications. The path ahead remains uncertain, but the company’s partnerships and cash reserves help anchor potential value for shareholders as the strategy evolves.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI